CV-BROWN modified.doc.doc.doc

736 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
736
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

CV-BROWN modified.doc.doc.doc

  1. 1. CURRICULUM VITAE A. PERSONAL INFORMATION Name: John Vincent Brown III, M.D. Date of Birth: February 11, 1958 Place of Birth: Kansas City, Missouri Business Address: 351 Hospital Road Suite 507 Newport Beach, CA 92663 (949) 642-1361 Fax (949) 642-1394 B. EDUCATION Undergraduate: University of Kansas B.S., 1980 Major: Organismal Biology Cumulative GPA 3.93 Graduation with Distinction Medical School: University of Kansas School of Medicine M.D., 1984 Position in Graduating Class, 24/144 Postgraduate University of California at Los Angeles Training: School of Medicine Division of Gynecologic Oncology Fellowship: July 1, 1988 to June 30, 1990 University of Washington Medical School Department of Obstetrics and Gynecology Residency: July 1, 1984 - June 30, 1988
  2. 2. JOHN VINCENT BROWN, M.D. CURRICULUM VITAE C. MEDICAL LICENSURE Washington: 025209 (1985) California: G62749 (1988) D. CERTIFICATION Diplomate of the American Board of Obstetrics and Gynecology (1991) Certificate of Special Qualification in Gynecologic Oncology (1994) Recertified in Obstetrics and Gynecology and Gynecologic Oncology (1999) E. PROFESSIONAL BACKGROUND ACADEMIC APPOINTMENTS Assistant Clinical Professor University of California at Los Angeles School of Medicine Harbor/UCLA Medical Center June 25, 1990 – 1999 Assistant Clinical Professor University of Southern California School of Medicine October, 1999—present PROFESSIONAL EMPLOYMENT Private Practice specializing in Gynecologic Oncology Newport Beach, CA 1990-present F. AWARDS Summerfield Scholar, 1977 Veta B. Lear Award (4.0 GPA for Freshman year), 1977 Owl Society (Junior Men's Honorary Society), 1979 Mortar Board, 1980 2
  3. 3. JOHN VINCENT BROWN, M.D. CURRICULUM VITAE Omicron Delta Kappa (Vice President), 1980 Educational Foundation Scholarship, 1980 Phi Kappa Phi, 1980 J. George Moore Award (Best paper by a fellow, Western Association Gynecologic Oncologists), 1990 G. PROFESSIONAL SOCIETIES American College of Obstetricians and Gynecologists (Fellow) Society of Gynecologic Oncologists (Member) American College of Surgeons (Fellow) American Society of Clinical Oncologists (Member) Western Association of Gynecologic Oncologists (Member) Society of Surgical Oncologists (Member) International Society of Gynecologic Cancer (Member) Pacific Coast Obstetrical and Gynecological Society (Member) H. PUBLICATIONS Brown JV, Stenchever MA. Cavernous lymphangioma of the vulva. Obstet Gynecol 1989;73:877-9. Brown JV, Fu YS, Berek JS. Ovarian metastases are rare in stage I adenocarcinoma of the cervix. Obstet Gynecol 1990;76:623-6. Brown JV, Peters WA, Corwin DJ. Invasive carcinoma after cone biopsy for cervical intraepithelial neoplasia. Gynecol Oncol 1991;40:25-28. Brown JV, Karlan BY, Greenspoon JS, Rosove MH, Lagasse LD. Perioperative coagulopathy in patients undergoing primary cytoreduction. Cancer 1993;71:2557-61. Malfetano J, Brown J, Abrams J, Homesley H, Benegno B, Braly P, Bean L, Malta E, Dziem G. Filgrastim (r-met-HuG-CSF) as an Adjunct to Cyclophosphamide and Carboplatin Chemotherapy in Advanced Ovarian Carcinoma. Proc Am Soc Clin Oncol 1993;12:265. 3
  4. 4. JOHN VINCENT BROWN, M.D. CURRICULUM VITAE Micha JP, Rettenmaier MA, Dillman R, Fraser P, Birk C, Brown JV. Single dose Dexamethasone Taxol premedication. Gynecol Oncol; 69:122-124, 1998. Micha JP, Brown JV. Primary surgical cure of stage III-B cervical carcinoma with adnexal metastasis. Gynecol Oncol; 71, 317-319, 1998 Micha JP, Rettenmaier MA, Francis L, Willenberg R, Brown JV. “Medically necessary” panniculectomy to facilitate radical pelvic surgery in morbidly obese patients. Gynecol Oncol; 69:237-242, 1998 Brown JV, Rettenmaier MA, Dillman R, Birk C, Culkin K, Micha JP. Three hour paclitaxel infusion and carboplatin is an effective outpatient treatment for stage III epithelial ovarian cancer. Gynecol Oncol; 68:166-168, 1998 Dillman RO, Nayak SK, Johnson D, Brown J, Chico S. The potential to use short-term cultures of ovarian cancer cells as autologous tumor cell vaccines. Proc Am Assoc Cancer Res 1997; 38:399, abstract 2676. Dillman RO, Nayak SK, Brown JV, Mahdavi K, Beutel LD. The feasibility of using short- term cultures of ovarian cancer cells for use as autologous tumor cell vaccines as adjuvant treatment of advanced ovarian cancer. Cancer Biother 1999;14:443-49. Brown JV, Peters WA, Rettenmaier MA, Karlan BY, Dillman RA, Smith MR, Drescher CW, Micha JP. A phase I trial of a 3-day Topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum. Gynecol Oncol 79; 2000. P Sabbatini, J Brown, Carol Aghajanian, M L Hensley, S Pezzulli, C O'Flaherty, M Lovegren, S Funt, M Warner, P Mitchell, M G Bolton, D Spriggs, B Duggan. A phase I/II study of PG-paclitaxel (CT-2103) in patients (pts) with recurrent ovarian, fallopian tube, or peritoneal cancer. Proc Am Soc Clin Oncol 2002; abstract 871. Brown JV, Peters WA, Rettenmaier MA, Dillman RA, Smith MR, Drescher CW, Micha JP. Three Consecutive Day Topotecan is an Active Regimen for Recurrent Epithelial Ovarian Cancer. Gynecol Oncol (Gynecol Oncol 2003;88:136-140) Rettenmaier MA, Brown JV, Micha JP. Modified vestibulectomy is inadequate treatment for secondary vulvar vestibulitis. Jnl Gynecol Surg 2003;19(1):13- 18. Micha JP, Goldstein BH, Rettenmaier MA, Mattison J, Graham C, Birk CL, Brown JV. Pilot Study of Outpatient Paclitaxel, Carboplatin and Gemcitabine for Advanced Stage Epithelial Ovarian, Peritoneal, and Fallopian Tube Epithelial Cancer. Gynecol Oncol 94:719-724, 2004 Micha JP, Goldstein BH, Hunter JV, Rettenmaier MA, Brown, JV. Long-term survival in 4
  5. 5. JOHN VINCENT BROWN, M.D. CURRICULUM VITAE an Ovarian Cancer Patient with Brain Metastases: A Case Report. Gynecol Oncol 2004;92:978-980. Brown JV, Goldstein BH, Rettenmaier MA, Aylward MM, Graham CL, Micha JP. Laser ablation of surgical margins following excisional partial vulvectomy for vulvar intraepithelial neoplasia may decrease recurrences. J Reprod Med 50(5):345, 2005 Rettenmaier MA, Micha JP, Brown JV, Goldstein B: Impact of Gynecologic Oncologists on Referral Patterns and Care of Patients with Uterine Malignancies at a Community Hospital. J Gynecol Surg 20(2):57-63, 2004 Micha JP, Goldstein BH, Rettenmaier MA, Brown JV. Cecal pelvic transposition following total pelvic exenteration. (Accepted for publication. Gynecol Oncol 2004). John P. Micha, Bram H Goldstein, Philip A Robinson, Mark A Rettenmaier, John V Brown. Abdominal/Pelvic Coccidioidomycosis. Gynecol Oncol 96(1):256-258, 2005 John P. Micha, Bram H Goldstein, Julie A Mattison, Kathy M Bader, Cheri Graham, Mark A Rettenmaier, John V Brown, Maurie Markman. Experience with single agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel and gemcitabine in advanced ovarian cancer. Gynecol Oncol 96(1):132-135, 2005 I. PRESENTATIONS Brown JV, Karlan BY, Lagasse LD. Improved cytoreduction with the Ultrasonic Surgical Aspirator. Western Association of Gynecologic Oncologists. May, 1989. Brown JV, Fu YS, Berek JS. Ovarian metastases are rare in stage I adenocarcinoma of the cervix. Western Association of Gynecologic Oncologists. June, 1990. Brown JV, Karlan BY, Rosove MH, Leuchter R, Futoran R, Lagasse LD. Perioperative coagulopathy in patients undergoing primary cytoreduction. Western Association of Gynecologic Oncologists. June, 1991. Brown JV, Rettenmaier MA, Micha JP. A pilot study of oral etoposide for recurrent or persistent ovarian cancer. Western Association of Gynecologic Oncologists. June, 1992. Brown JV, Rettenmaier MA, Micha JP, Tullio R, Burke C. Taxol and Carboplatin is an effective outpatient regimen for advanced ovarian cancer. Western Association of Gynecologic Oncologists. June, 1995. Dillman RO, Nayak SK, Johnson D, Brown J, and Chico S. The potential to use short-term cultures of ovarian cancer autologous tumor cell vaccines. American Asssociation for 5
  6. 6. JOHN VINCENT BROWN, M.D. CURRICULUM VITAE Cancer Research. March, 1997. Brown JV, Peters WA, Rettenmaier MA, Karlan BY, Dillman RA, Smith MR, Drescher CW, Micha JP. A phase I trial of a 3-day Topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum. Society of Gynecologic Oncologists. February, 2000. Brown JV, Peters WA, Rettenmaier MA, Dillman RA, Smith MR, Drescher CW, Micha JP. Three Consecutive Day Topotecan is an Active Regimen for Recurrent Epithelial Ovarian Cancer. Society of Gynecologic Oncologists. March, 2002. P Sabbatini, J Brown, Carol Aghajanian, M L Hensley, S Pezzulli, C O'Flaherty, M Lovegren, S Funt, M Warner, P Mitchell, M G Bolton, D Spriggs, B Duggan. A phase I/II study of PG-paclitaxel (CT-2103) in patients (pts) with recurrent ovarian, fallopian tube, or peritoneal cancer. American Society of Clinical Oncologists. May, 2002. Sabbatini P, Brown J, Bolton M. Phase I/II study of PG-paclitaxel (CT 2103) in patients with recurrent ovarian cancer. European Spring Oncology Conference. June, 2002. Sabbatini P, Brown J, Peters WA, Andrew J, Mehdi A, Crozier MA, Rivkin S, Bolton MG. Phase I/II study of CT-2103 (Xyotax) in patients with recurrent ovarian cancer. Memorial Sloan-Kettering Cancer Center, New York, NY; Gynecologic Oncology Associates, Newport Beach, CA; Pacific Gynecology Specialists; Virginia Mason Medical Center; Stockton Hematology Oncology Medical Group; Southwest Regional Cancer Cancer Center; Swedish Medical Center and Tumor Institute; Cell Therapeutics, Inc, Seattle, WA. European Organisation for Research and Treatment of Cancer (EORTC). November, 2002. Peters WA, Brown JV, Rivkin S, Bolton MG, Sabbatini P. Phase I/II Study of CT-2103 (Xyotax) in Patients with Recurrent Ovarian Cancer. Society of Gynecologic Oncologists. February, 2003. Brown JV, Goldstein BH, Rettenmaier MA, Aylward MM, Graham CL, Micha JP. Laser ablation of surgical margins following excisional partial vulvectomy for vulvar intraepithelial neoplasia may decrease recurrences. Pacific Coast Obstetrical and Gynecological Society. September, 2003. Micha, JP, Goldstein BH, Rettenmaier, MA, Mattison J, Graham CL, Birk CL, and Brown JV. Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube epithelial cancer. Eli Lilly Investigators Meeting March 2003, Phoenix, AZ. Micha, JP, Goldstein BH, Rettenmaier, MA, Mattison J, Graham CL, Birk CL, and Brown JV. Paclitaxel, carboplatin and gemcitabine for treatment of advanced stage ovarian cancer. Eli Lilly Investigators Meeting April 2004, Phoenix, AZ. 6
  7. 7. JOHN VINCENT BROWN, M.D. CURRICULUM VITAE J. RESEARCH GRANTS. Bristol Myers Squibb Principle Investigator Phase I/II study of intravenous paclitaxel and carboplatin in patients with stage III/IV epithelial ovarian cancer (Three hour paclitaxel infusion) Principle Investigator Phase II study of intravenous paclitaxel and carboplatin in patients with stage III/IV epithelial ovarian cancer (One hour paclitaxel infusion) Amgen Co-Principle Investigator Filgrastim (r-met-HuG-CSF) as an Adjunct to Cyclophosphamide and Carboplatin Chemotherapy in Advanced Ovarian Carcinoma Smith Kline Beecham Principle Investigator A phase I/II trial of topotecan in patients with platinum and taxane refractory epithelial ovarian cancer Principle Investigator A phase II trial of three day topotecan q 21 days for recurrent epithelial carcinomas of the ovary, fallopian tube, and peritoneum. Eli Lilly Sub - Investigator Phase II Trial of Intravenous Taxol, Carboplatin, and Gemzar in Patients With Stage III/IV Epithelial Ovarian Cancer, Stage III/IV Fallopian Tube Epithelial Cancer, Stage III/IV Endometrial Adenocarcinoma, Stage III/IV Malignant Primary Peritoneal Mesothelioma, and Stage III/IV Peritoneal Cancer Eli Lilly Principle Investigator A Phase II Study of Gemcitabine and Carboplatin in Patients with Advanced, Persistent, or Recurrent Carcinoma of the Cervix Ortho Biotech Principle Investigator A Phase II Trial of Doxil and Carboplatin for the Treatment of Advanced, Recurrent, or Persistent Endometrial Carcinoma Cellpath Sub – Investigator A Phase II Trial of CP4071 (Digitoxin) In Patients With Recurrent Epithelial 7
  8. 8. JOHN VINCENT BROWN, M.D. CURRICULUM VITAE Mullerian Adenocarcinoma Altarex Sub – Investigator A randomized, double-blind, placebo-controlled, phase IIB study of the safety and efficacy of OvaRex (MAb-B43.13) in ovarian cancer patients with an elevated serum CA-125 but without other evidence of disease Altarex Sub – Investigator A multi-center clinical trial of intravenous OvaRex (MAb-B43.13) as post- chemotherapy consolidation for ovarian, tubal and peritoneal carcinoma Atairgin Technologies, Inc. Sub – Investigator A clinical protocol to evaluate the role of lysophosphatidic acid as an aid in the differential diagnosis of ovarian cancer in women scheduled for surgery with a pelvic mass or a suspected ovarian malignancy Atairgin Technologies, Inc. Sub – Investigator A protocol to characterize lysophosphatidic acid assay levels in women not suspected of ovarian cancer Eli Lilly Sub – Investigator A Randomized Phase III Trial of Gemzar versus Doxil with Crossover Treatment Option for Patients with Platinum-Resistant Ovarian, Fallopian Tube, Peritoneal Cancer. GlaxoSmithKline Principle Investigator A Phase II, Multi-Center Trial of Weekly Topotecan in Patients With Recurrent Platinum Sensitive Epithelial Cancers of the Ovary, Fallopian Tube, and Peritoneum The ANA Study Group Sub – Investigator The ANC Study Group Registry: A Prospective Study of Neutropenic Complications 8
  9. 9. JOHN VINCENT BROWN, M.D. CURRICULUM VITAE Online Collaborative Oncology Group (OCOG) Sub – Investigator A Randomized, Open-Label Study to Assess Time to Hemoglobin Response of a Front Load Dosing Regimen for Darbepoetin Alfa Compared to a Weekly Dose Regimen for Recombinant Human Erythropoietin in Patients with Non-Myeloid Malignancies Receiving Chemotherapy Unither Sub – Investigator A Double Blind, Placebo-Controlled, Multicenter Clinical Trial Of Intravenous OvaRex Mab-B43.13 As Post-Chemotherapy Consolidation For Epithelial Carcinoma Of Ovarian, Tubal Or Peritoneal Origin Cell Therapeutics Site Principal Investigator A phase I/II study of PG-paclitaxel (CT-2103) in patients (pts) with recurrent ovarian, fallopian tube, or peritoneal cancer Telik Sub – Investigator Phase 3 Randomized Study of TLK286 versus Doxil/Caelyx or Hycamptin as Third- Line Therapy in Platinum Refractory or resistant Ovarian Cancer Cell Therapeutics Principle Investigator CT-2103/Carboplatin for Patients with Newly Diagnosed Stage III or IV Ovarian or Primary Peritoneal Cancer: A Phase II Study K. COMMITTEES Obstetrics and Gynecology Core Committee, Irvine Medical Center Society of Gynecologic Oncology Education and Exhibit Ad Hoc Committee: 1997-1999. Cancer Committee, Hoag Memorial Presbyterian Hospital: 2000-present. Society of Gynecologic Oncology Clinical Practice Committee: 2001-present. Co-Chair of Society of Gynecologic Oncology Clinical Practice Committee: 2004-present. American College of Surgeons Committee on Applicants: 1998-present. Obstetrics and Gynecology Core Committee, Hoag Memorial Presbyterian Hospital: 2003- 9
  10. 10. JOHN VINCENT BROWN, M.D. CURRICULUM VITAE present. Revised 7/5/04 10

×